Products for Research Use Only

Mitazalimab

CAT: 0804-HY-P99742-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99742-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment[1][2].
CAS Number
2055640-86-1
Product Name Alternative
ADC-1013; JNJ-64457107
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mitazalimab.html
Purity
99.23
Solubility
10 mM in DMSO
Smiles
[Mitazalimab]
Molecular Weight
(143.44 kDa)
References & Citations
[2]Smith K E, et al. Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells[J]. Cancer Research, 2022, 82 (12_Supplement) : 4155-4155. |[1]Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70 (12) :3629-3642.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
TNFRSF5/CD40

Popular Products